What is the current stock price of Schrödinger, Inc. (SDGR)?

As of the latest market data, Schrödinger, Inc. (SDGR) is trading at $12.34. The stock has seen a gain of 2.32% today.

Does Schrödinger, Inc. (SDGR) pay a dividend?

Based on current data, Schrödinger, Inc. does not have a confirmed active dividend policy.

What is the market cap of Schrödinger, Inc.?

The current market capitalization of Schrödinger, Inc. (SDGR) is approximately unavailable.

SDGR

Schrödinger, Inc.·Healthcare

12.34

2.322%(+0.28)

Close Price

12.49

1.216%(+0.15)

Pre-Market

Last Updated: — ET

52W L: $10.9552W H: $27.63

SDGR NEWS

defenseworld.net

1d ago

Ramy Farid Sells 43,000 Shares of Schrodinger (NASDAQ:SDGR) Stock

Schrodinger, Inc. (NASDAQ: SDGR - Get Free Report) CEO Ramy Farid sold 43,000 shares of the company's stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $12.33, for a total value of $530,190.00. Following the transaction, the chief executive officer directly owned 330,824 shares in the company, valued

businesswire.com

2d ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2026, the company granted restricted stock units (RSUs) with respect to 4,253 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t.

defenseworld.net

Mar 28

Schrodinger, Inc. (NASDAQ:SDGR) Given Average Recommendation of “Hold” by Brokerages

Schrodinger, Inc. (NASDAQ: SDGR - Get Free Report) has been given an average recommendation of "Hold" by the nine ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company.

seekingalpha.com

Mar 23

Schrödinger, Inc. (SDGR) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

businesswire.com

Mar 18

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 14, 2026, the company granted (i) a non-statutory stock option to purchase 1,950 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 4,375 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of t.

seekingalpha.com

Mar 6

Schrödinger, Inc. (SDGR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Company Profile

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Sector

Healthcare

Industry

Medical - Healthcare Information Services

Employees

891

IPO Date

2020-02-06

Beta

1.62

Websitewww.schrodinger.com↗